Upperton Pharma Solutions, a leading UK-based contract development and manufacturing organisation (CDMO), continues its growth following the build of a new sterile manufacturing facility with the appointment of Michael Mellor-Clark as Chief Commercial Officer (CCO).
Michael joins the company in a period of sustained growth and expansion and will work with Upperton’s leadership team and Board to drive the commercial strategy and guiding the next stage of Upperton’s growth into sterile delivery and commercial manufacturing across the EU and US.
Michael has over 25 years’ experience in leading commercial operations and managing the integration of business development in an international environment across Asia-Pacific, Europe and North America.
He joins Upperton following senior roles at Concept Life Sciences, PathoQuest, and BioReliance (Merck).
Michael said: “I am delighted to be joining Upperton at such a pivotal time in their history. Being part of the continued growth and leading the commercial aims is an exciting role, and I’m pleased to be part of a great team that puts clients and patients at the heart of everything they do.”
Nikki Whitfield, Chief Executive Officer of Upperton Pharma Solutions, said:
“Mickhael joins us as we finalise our sterile facility operations and continue to expand our CDMO offering into one that puts everything in one place for our customer. His experience and leadership skills will be a strong addition to our team, providing strategic knowledge that will support our aim to be the CDMO partner of choice for many small to medium sized biotech and pharmaceutical companies.”
Upperton Pharma Solutions specialises in formulation development, clinical trial manufacturing, and commercial manufacturing across various dosage forms, including oral solids, liquids, semi-solids, inhalation and sterile products. With a state-of-the-art 60,000ft² facility in Nottingham, UK, covering sterile and on-sterile dosage forms, the company offers integrated CDMO services from pre-clinical development through to market supply.
Upperton were recently recognised at the CDMO Leadership Awards 2025 as the Champion Winner of the Small Molecule Dosage Form International category.